Drug Trial Radar · NCT02081300
Safety and Efficacy of Oral LPCN 1021 in Men With Low Testosterone or Hypogonadism
Last checked: Nov 19, 2026Latest source record: Oct 23, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
315
Actual
Start
Feb 2014
Primary completion
May 2015
Study completion May 2015
Sponsor
- Lead sponsor
- Lipocine Inc.Industry
- Sponsor type
- Industry
- Collaborators
- Syneos Health; PPD Development, LP
- First posted
- Mar 7, 2014
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- Male only, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to determine the safety and efficacy of an oral testosterone undecanoate formulation for use as testosterone-replacement therapy in men with low testosterone.
Conditions
- Male Hypogonadism
Interventions
Oral testosterone undecanoate, LPCN 1021Drug
Topical testosterone gel 1.62 %Drug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of LPCN 1021-treated subjects who achieve a total testosterone concentration [Cavg] between 300 - 1140 ng/dL.Time frame: Following 13 weeks of treatment
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.